PFE
Pfizer: a cheap multiple and heavy free cash flow — and the most bearish analyst coverage in this group
A 2-of-4 scorecard pairs cash-backed profits and a 19.6% free-cash-flow margin with declining revenue and earnings. The stock trades at 19x earnings, 8% below its high — but only 23% of 12 analysts rate it Buy, against 60% Hold and 17% Sell. Current price: $25.92.
pharmadividendpatent-cliff